Find and Replace: R&D Investment Following the Erosion of Existing Products

References

• Agha L, Zeltzer D (2019) Drug diffusion through peer networks: The influence of industry payments. NBER Working Paper No. 26751, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Arora A, Fosfuri A, Gambardella A (2004) Markets for Technology: The Economics of Innovation and Corporate Strategy (MIT Press, Cambridge, MA).Google Scholar
• Arrow KJ (1962) The economic implications of learning by doing. Rev. Econom. Stud. 29(3):155–173.Crossref, Google Scholar
• Autor D, Dorn D, Hanson GH, Pisano G, Shu P (2020) Foreign competition and domestic innovation: Evidence from US patents. Amer. Econom. Rev. (Insights), 2(3):357–74.Google Scholar
• Ball GP, Macher JT, Stern AD (2018) Negative shocks and innovation: Evidence from medical device recalls. Harvard Business School Working Paper No. 19-028, Harvard Business School, Boston.Google Scholar
• Bena J, Li K (2014) Corporate innovations and mergers and acquisitions. J. Finance 69(5):1923–1960.Crossref, Google Scholar
• Bertrand M, Mullainathan S (2003) Enjoying the quiet life? Corporate governance and managerial preferences. J. Political Econom. 111(5):1043–1075.Crossref, Google Scholar
• Bertrand M, Mullainathan S (2005) Profitable investments or dissipated cash? Evidence on the investment-cash flow relationship from oil and gas lease bidding. NBER Working Paper No. 11126, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Bertrand M, Duflo E, Mullainathan S (2004) How much should we trust differences-in-differences estimates? Quart. J. Econom. 119(1):249–275.Crossref, Google Scholar
• Blankshain J, Carpenter D, Moffitt S (2013) R&D abandonment in regulatory equilibrium: Evidence from asset price shocks induced by FDA decisions. Working paper, Harvard University, Cambridge, MA.Google Scholar
• Bloom N, Draca M, Van Reenen J (2016) Trade induced technical change? The impact of Chinese imports on innovation, IT and productivity. Rev. Econom. Stud. 83(1):87–117.Crossref, Google Scholar
• Bloom N, Schankerman M, Van Reenen J (2013b) Identifying technology spillovers and product market rivalry. Econometrica 81(4):1347–1393.Crossref, Google Scholar
• Bloom N, Romer PM, Terry SJ, Van Reenen J (2013a) A trapped-factors model of innovation. Amer. Econom. Rev. 103(3):208–213.Crossref, Google Scholar
• Carey C, Lieber EM, Miller S (2021) Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. J. Public Econom. 197:104402.Google Scholar
• Cassiman B, Veugelers R (2006) In search of complementarity in innovation strategy: Internal R&D and external knowledge acquisition. Management Sci. 52(1):68–82.Link, Google Scholar
• Ceccagnoli M, Higgins MJ, Palermo V (2014) Behind the scenes: Sources of complementarity in R&D. J. Econom. Management Strategy 23(1):125–148.Crossref, Google Scholar
• Chan T, Nickerson JA, Owan H (2007) Strategic management of R&D pipelines with cospecialized investments and technology markets. Management Sci. 53(4):667–682.Link, Google Scholar
• Christensen CM (2013) The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business Review Press, Brighton, MA).Google Scholar
• Cohen WM, Levinthal DA (1989) Innovation and learning: The two faces of R&D. Econom. J. (London) 99(397):569–596.Google Scholar
• Cunningham C, Ederer F, Ma S (2021) Killer acquisitions. J. Political Econom. 129(3):649–702.Google Scholar
• Danzon PM, Epstein A, Nicholson S (2007) Mergers and acquisitions in the pharmaceutical and biotech industries. Managerial Decision Econom. 28(4-5):307–328.Crossref, Google Scholar
• Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS (2017) Association between FDA black box warnings and Medicare formulary coverage changes. Amer. J. Managed Care 23(9):e310–e315.Google Scholar
• Freedman S, Kearney M, Lederman M (2012) Product recalls, imperfect information, and spillover effects: Lessons from the consumer response to the 2007 toy recalls. Rev. Econom. Statist. 94(2):499–516.Crossref, Google Scholar
• Gans JS, Stern S (2003) The product market and the market for “idea”: Commercialization strategies for technology entrepreneurs. Res. Policy 32(2):333–350.Crossref, Google Scholar
• Grennan M, Myers K, Swanson A, Chatterji A (2018) Physician-industry interactions: Persuasion and welfare. NBER Working Paper No. 26751, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Hall BH, Lerner J (2010) The financing of R&D and innovation. Hall BH, Rosenberg N, eds. Handbook of the Economics of Innovation vol. 1 (North Holland, Amsterdam), 609–639.Crossref, Google Scholar
• Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nature Biotechnology 32(1):40–51.Crossref, Google Scholar
• Henderson R, Cockburn I (1994) Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management J. 15(S1):63–84.Crossref, Google Scholar
• Hermosilla M (2021) Rushed innovation: Evidence from drug licensing. Management Sci. 67(1):257–278.Google Scholar
• Higgins MJ, Rodriguez D (2006) The outsourcing of R&D through acquisitions in the pharmaceutical industry. J. Financial Econom. 80(2):351–383.Crossref, Google Scholar
• Higgins MJ, Yan X, Chatterjee C (2018) Market effects of adverse regulatory events: Evidence from drug relabeling. NBER Working Paper No. 24957, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Jarrell G, Peltzman S (1985) The impact of product recalls on the wealth of sellers. J. Political Econom. 93(3):512–536.Crossref, Google Scholar
• Kang H, Park HD (2019) Patent cliffs and the congruence between structure and investment strategy in corporate venture capital activities: Evidence from the biopharmaceutical sector. Working paper, Berry College, Mount Berry, Georgia.Google Scholar
• Krieger JL, Li D, Papanikolaou D (2022) Missing novelty in drug development. Rev. Financial Stud. 35(2):636–679.Google Scholar
• Lamont O (1997) Cash flow and investment: Evidence from internal capital markets. J. Finance 52(1):83–109.Crossref, Google Scholar
• Lerner J, Merges RP (1998) The control of technology alliances: An empirical analysis of the biotechnology industry. J. Indust. Econom. 46(2):125–156.Crossref, Google Scholar
• Lerner J, Shane H, Tsai A (2003) Do equity financing cycles matter? Evidence from biotechnology alliances. J. Financial Econom. 67(3):411–446.Crossref, Google Scholar
• Letina I (2016) The road not taken: Competition and the R&D portfolio. RAND J. Econom. 47(2):433–460.Crossref, Google Scholar
• Lucking B, Bloom N, Van Reenen J (2019) Have R&D spillovers declined in the 21st century? Fiscal Studies 40.4:561–590.Google Scholar
• Ma S (2020) The life cycle of corporate venture capital. Rev. Financial Stud. 33(1):358–394.Crossref, Google Scholar
• Ma P, Marinovic I, Karaca-Mandic P (2015) Drug manufacturers’ delayed disclosure of serious and unexpected adverse events to the US Food and Drug Administration. JAMA Intern. Med. 175(9):1565–1566.Crossref, Google Scholar
• Macher JT, Wade JB (2018) The black box of strategy: Competitive responses to and performance from adverse events. Working paper, Georgetown University, Washington, DC.Google Scholar
• Maksimovic V, Phillips G (2001) The market for corporate assets: Who engages in mergers and asset sales and are there efficiency gains? J. Finance 56(6):2019–2065.Crossref, Google Scholar
• Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S (2020) Trends in industry payments to physicians in the United States from 2014 to 2018. JAMA 324(17):1785–1788.Crossref, Google Scholar
• Metrick A, Nicholson S (2009) Do financial constraints have a real effect on pharmaceutical and biotech investment. Working paper, Yale School of Management, New Haven, CT.Google Scholar
• Morck R, Shleifer A, Vishny RW (1990) Do managerial objectives drive bad acquisitions? J. Finance 45(1):31–48.Crossref, Google Scholar
• Rhodes-Kropf M, Robinson DT (2008) The market for mergers and the boundaries of the firm. J. Finance 63(3):1169–1211.Crossref, Google Scholar
• Scharfstein DS, Stein JC (2000) The dark side of internal capital markets: Divisional rent-seeking and inefficient investment. J. Finance 55(6):2537–2564.Crossref, Google Scholar
• Schumpeter J (1942) Creative Destruction. Capitalism, Socialism, Democracy (Harper & Brothers, New York), 82–85.Google Scholar
• Sevilir M, Tian X (2012) Acquiring innovation. Working paper, Indiana University, Bloomington.Google Scholar
• Shin H-H, Stulz RM (1998) Are internal capital markets efficient? Quart. J. Econom. 113(2):531–552.Crossref, Google Scholar
• Stein JC (1997) Internal capital markets and the competition for corporate resources. J. Finance 52(1):111–133.Crossref, Google Scholar
• Teece DJ (1986) Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy 15(6):285–305.Crossref, Google Scholar
• Thakor RT, Lo AW (2021) Competition and R&D financing: Evidence from the biopharmaceutical industry. J. Financial Quant. Anal. 1–69.Google Scholar
• Thakor RT, Anaya N, Zhang Y, Vilanilam C, Siah KW, Wong CH, Lo AW (2017) Just how good an investment is the biopharmaceutical sector? Nature Biotechnology 35(12):1149.Crossref, Google Scholar
• Vickrey W (1961) Counterspeculation, auctions, and competitive sealed tenders. J. Finance 16(1):8–37.Crossref, Google Scholar